ROAD MAP

Integrating artificial intelligence in drug discovery and early drug development

Cancerappy Participates in New Scientific Publication on AI in Drug Discovery We’re proud to announce that Cancerappy has contributed to a recently published paper in Biomarker Research titled "Artificial intelligence in drug discovery and early development: current...

Cancerappy: Using AI to Advance Cancer Research

Since 2019, Cancerappy has been harnessing the power of artificial intelligence to transform cancer research, from improving detection and diagnosis to developing more effective treatments with fewer side effects. We’re putting AI to work in areas like genomics,...

Cancerappy at #Bventure24

We’re back at Bventure! Cancerappy is actively participating in this innovation event through the University of Deusto, joining the roundtable discussion, “The Value of Talent in an AI Startup.” On Tuesday, Oct 15th, our CEO will share insights on how AI is impacting...

CancerAppy to Speak at ACCESS CHINA Partnering Forum

We are glad to announce that Luis Martin, the Chief Executive Officer of CancerAppy, will be presenting at the ACCESS CHINA Partnering Forum – Autumn Virtual Showcase during September 24th to 25th, and 27th, 2024. ACCESS CHINA Biotech Forum is the largest corporate...

China health innovation ecosystem

A Cancerappy delegation has participated in a roadshow of European companies to learn about the innovative health ecosystem in the Shanghai and Wuxi area. Our CEO has had the opportunity to hold various meetings with different agents of the innovation ecosystem,...

CancerAppy Contributes to Innovative Scientific Paper on ADCs in Clinical Use

CancerAppy pioneers in ADC research, contributing to a transformative scientific paper. Our team's dedication unveils insights on payload properties, shaping the future of ADC therapies. A crucial leap in cancer treatment. We are proud to announce our significant...

CancerAppy at ESMO Congress: Pioneering Research Unveiled!

CancerAppy's groundbreaking study at ESMO Congress (Oct '23) reveals profound insights into Treg impact on tumor immune responses. Unearthing common transcripts and potential predictors, our AI-driven research shapes the future of cancer treatment.CancerAppy has...

2023

2022

CA05 Lead Identification

We have identified insilico, several compounds as inhibitors of CA05, which is a protein kinase overexpressed in various types of tumors with a clear oncogenic role and no type-specific inhibitor, and we have started in vitro trials to select a lead.

CA02/03 Target Identification vs NSCLC

CancerAppy has identified two membrane proteins that are upregulated in NSCLC and has patented their use as targets to vectorize compounds against these tumors, or as surrogates for immune activation, to select patients o explore combinations with new immune therapies

2021

4YFN 2021

Cancerappy has been selected to participate in the Espacio España 4YFN 2021.  

2020

2019